9939 — Kintor Pharmaceutical Cashflow Statement
0.000.00%
- HK$514.62m
- HK$499.28m
- CNY5.00m
Annual cashflow statement for Kintor Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -508 | -842 | -953 | -1,069 | — |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 134 | 66.5 | 173 | 761 | — |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -13.4 | -286 | -199 | -98.7 | -199 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -381 | -1,051 | -961 | -388 | -199 |
Capital Expenditures | -96.2 | -106 | -27.6 | -2.72 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -344 | 198 | 94.8 | 6 | 20 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -440 | 92 | 67.2 | 3.27 | 20 |
Financing Cash Flow Items | -29.1 | -2.03 | 0 | — | -120 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1,780 | 857 | 816 | -33.5 | -120 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 869 | -138 | -61.9 | -420 | -297 |